UK markets closed

DiaMedica Therapeutics Inc. (DMAC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.50+0.03 (+0.46%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.47
Open6.45
Bid6.26 x 3000
Ask7.41 x 1400
Day's range6.36 - 6.71
52-week range3.77 - 10.88
Volume112,094
Avg. volume118,096
Market cap122.11M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.79
Earnings date09 Aug 2021 - 13 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est25.33
  • DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2021 Financial Results
    Business Wire

    DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2021 Financial Results

    DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended March 31, 2021. DiaMedica will host a conference call Thursday, May 6, 2021, at 7:00 a.m. Central Time to discuss its business update and first quarter financial results.

  • DiaMedica Therapeutics to Report First Quarter 2021 Financials and Provide a Business Update May 6, 2021
    Business Wire

    DiaMedica Therapeutics to Report First Quarter 2021 Financials and Provide a Business Update May 6, 2021

    DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2021 financial results will be released after the markets close on Wednesday, May 5th. DiaMedica will host a live conference call on Thursday, May 6th at 7:00 AM Central Time to discuss its business update and financial results.

  • DiaMedica Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference
    Business Wire

    DiaMedica Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference

    DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Rick Pauls, President and CEO, will deliver a corporate presentation at B. Riley’s Neuroscience Investor Conference on Thursday, April 29th at 11:30am ET. DiaMedica will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through B. Riley.